Disruptive Dose with Anton Yarovoy

Pharma Marketing Executive

In this DHCG Disruptive Dose, Mark Bard sits down with Anton Yarovoy, a precision oncology marketing leader with a background in scientific research, to explore what it takes to connect patients with the right therapy at the right time. Drawing on his Star Wars analogy for precision medicine, Anton makes the case that understanding the mechanics driving a cancer is what separates a targeted strike from a broad and ineffective approach. The conversation covers the critical role of testing state awareness in launch strategy, why co-developing content with advocacy organizations and HCPs is essential to building patient trust, and how AI search is reshaping the information landscape in ways pharma cannot afford to ignore. Anton also addresses the growing reality that patients, caregivers, and family members are all doing their own research — often landing on HCP content — and why pharma brands must build bridges across their entire content ecosystem to be the credible source of truth when it matters most.